Jacqueline Vuky is an Oncology physician affiliated with Oregon Health & Science University. OpenAlex indexes 91 publications with 4,599 citations (h-index 30); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1130 NW 22nd Ave
Suite 100
Portland, OR 972102934
Telephone
503-299-6500Registry record last updated 25 Apr 2012.
Clinical trials
- Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer
Sponsor: Benaroya Research Institute
- Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
Sponsor: Benaroya Research Institute
- Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Sponsor: Virginia Mason Hospital/Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20251 payment
- Genentech, Inc.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57.7%Cytochrome P450 17A1 Inhibitor32.7%Abiraterone Acetate100%Part D≥23 patientsAndrogen Receptor Inhibitor14.4%Xtandi100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
33.7%Corticosteroid33.7%Prednisone100%Part D≥27 patientsHormonal (systemic)
4.5%l-Thyroxine4.5%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
New England Journal of Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”